Cozen O’Connor: Xarelto User Faces Hard Sell In 1st Philly Mass Tort Trial

Xarelto User Faces Hard Sell In 1st Philly Mass Tort Trial

Friday, November 3, 2017

James Heller, chair of Cozen O'Connor's Products Liability Practice Group, was quoted in Law 360's article, "Xarelto User Faces Hard Sell In 1st Philly Mass Tort Trial." As the first Philadelphia trial over alleged injuries from the blood-thinner Xarelto prepares to open on Monday, attorneys say defense verdicts notched by Johnson & Johnson and Bayer AG in three bellwether federal cases over the drug earlier this year show the challenge for plaintiffs in proving their claims. "The most interesting thing to me about the first three cases was not necessarily that they were all defense verdicts, but that they were rapid defense verdicts," Jim said. "That tells me that not only did they find the evidence supportive of the defense, but that they found it overwhelming."

To read the full article, click here.